HENGRUI PHARMA (600276.SH) announced that it has entered into an Exclusive Licensing Agreement with Hansoh Pharmaceutical Group Co., Ltd. ("HANSOH PHARMA"), granting HANSOH PHARMA a paid license for its SHR6508 project. Concurrently, HENGRUI PHARMA's subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd. ("Chengdu Shengdi"), has signed a Commercial Service Framework Agreement with HANSOH PHARMA's subsidiary, Jiangsu Haosen Pharmaceutical Group Co., Ltd. ("Haosen Pharmaceutical"), authorizing Haosen Pharmaceutical to provide non-exclusive commercial services for the company's Paricalcitol Soft Capsule product. According to the announcement, SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease requiring hemodialysis; it is currently undergoing Phase III clinical trials. The calcium-sensing receptor monitors and regulates calcium levels by controlling the release of parathyroid hormone (PTH), which governs blood calcium levels. Due to its enhanced sensitivity to calcium ions, administration of SHR6508 can reduce PTH secretion in hemodialysis patients with secondary hyperparathyroidism. Paricalcitol is a synthetic vitamin D analog that inhibits the secretion of parathyroid hormone (PTH) by binding to the vitamin D receptor, thereby lowering serum PTH levels. The company's Paricalcitol Soft Capsule received approval for market launch from the National Medical Products Administration (NMPA) in November 2025. The announcement further indicates that HANSOH PHARMA and Haosen Pharmaceutical are controlled by the spouse of HENGRUI PHARMA's actual controller and Chairman, Mr. Sun Piaoyang, and are therefore considered connected parties of the company under the listing rules. HANSOH PHARMA is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Haosen Pharmaceutical, focusing on major therapeutic areas such as anti-tumor, anti-infective, central nervous system, metabolic, and autoimmune diseases.
- Like
- Comment
- Favorite
HENGRUI PHARMA (600276.SH) Signs Exclusive Licensing Agreement with HANSOH PHARMA for SHR6508 Project
Stock News2025-12-28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet